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Abstract 
 NO is a pleiotropic signaling molecule and has an important role for cognition and 
emotion. In the brain, NO is produced by neuronal nitric oxide synthase (NOS-I, encoded by 
NOS1) coupled to the NMDA receptor via PDZ interactions; this protein-protein interaction is 
disrupted upon binding of NOS1 adaptor protein (encoded by NOS1AP) to NOS-I. As both 
NOS1 and NOS1AP were associated with schizophrenia, we here investigated these genes in 
greater detail by genotyping new samples and conducting a meta-analysis of our own and 
published data. In doing so, we confirmed association of both genes with schizophrenia and 
found evidence for their interaction in increasing risk towards disease. Our strongest finding 
was the NOS1 promoter SNP rs41279104, yielding an odds ratios of 1.29 in the meta-
analysis. As findings from heterologous cell systems have suggested that the risk allele 
decreases gene expression, we studied the effect of the variant on NOS1 expression in 
human post-mortem brain samples and found that the risk allele significantly decreases 
expression of NOS1 in the prefrontal cortex. Bioinformatic analyses suggest that this might 
be due the replacement of six transcription factor binding sites by two new binding sites as a 
consequence of proxy SNPs. Taken together, our data argue that genetic variance in NOS1 
resulting in lower prefrontal brain expression of this gene contributes to schizophrenia 
liability, and that NOS1 interacts with NOS1AP in doing so. The NOS1-NOS1AP PDZ interface 
may thus well constitute a novel target for small molecules in at least some forms of 
schizophrenia. 
 
Introduction 
 Nitric oxide (NO) is a gaseous messenger with atypical properties, acting in a 
pleiotropic manner by guanylyl cyclase activation and also direct nitrosylation of target 
proteins including CREB and thereby genomic effector mechanisms. In the brain, NO is 
produced by the neuronal isoform of nitric oxide synthase, NOS-I, which is encoded by the 
NOS1 gene located on chromosome 12q24.2-.3. Approximately one percent of all neurons 
express NOS-I, with almost every neuron in the brain receiving input from a NOS-I positive 
cell. However, the highest levels of NOS-I can be found in the cerebellum, cortex, basal 
ganglia, hypothalamus, and hippocampus. NOS-I occurs in various neuronal subtypes. Its 
most prominent functional interaction partner in excitatory neurons, e.g. in the cortex and 
the hippocampus, is the glutamatergic NMDA receptor. NOS-I is activated by calcium influx 
through the NMDA receptor and coupled to the site of action via the postsynaptic density, a 
protein scaffold comprising inter alia of the proteins PSD-93/-95, SHANK, and DLGAP. The so-
called NOS1 adaptor protein NOS1AP (previously termed CAPON, carboxy terminal PDZ 
domain ligand of neuronal NO synthase) competes with PSD-93/-95 for NOS-I binding and 
has both a PDZ as well as an N-terminal phosphotyrosine binding (PTB) domain which allows 
it to connect NOS-I to synapsin, forming a ternary NOS-I – NOS1AP – synapsin complex 
(Jaffrey et al., 2002). Also, the NOS-I – NOS1AP complex can bind to RASD1 (also known as 
DEXRAS1) (Fang et al., 2000), which belongs to the superfamily of small GTPases and itself is 
activated by NO (Fang et al., 2000; Jaffrey et al., 2002). This is accomplished upon NOS1AP 
binding, resulting in S-nitrosylation of a cysteine residue. Another protein that interacts with 
NOS-I at this site is DYNLL1 (dynein, light chain, LC8-type 1), previously termed PIN (protein 
inhibitor of NOS-I), although specificity of this interaction and its mechanism were later 
questioned. Rather, it might function as part of the neuronal machinery serving the axonal 
transport of NOS-I, as it was shown to be part of the microtubule-associated motor protein 
dynein complexes and hence termed dynein light chain of 8 kDa (LC8, DLC1). It is thought to 
link the dynein complex to cargo molecules including NOS-I (Rodriguez-Crespo et al., 2001), 
DLGAP1, GluN3A and PSD-95 (Navarro-Lerida et al., 2004) supporting the notion that DYNLL1 
serves as a transport adaptor vehicle for proteins which constitute the glutamatergic 
postsynaptic complex. This is underscored by data showing that DYNLL1 is also part of the 
above mentioned NMDA – PSD-95 – NOS-I – DLGAP1 complex, probably trafficking this 
complex along microtubules and actin cytoskeleton (Haraguchi et al., 2000).  
 Both NOS-I as well as NOS1AP have repeatedly been suggested to be involved in the 
pathogenesis of schizophrenia which relates to the “glutamatergic” theory of schizophrenia 
and the role of NO in mediating NMDA receptor-mediated signaling. While there are 
numerous studies on animal models or post-mortem findings, reviewed elsewhere (NOS: 
(Bernstein et al., 2011); NOS1AP: (Brzustowicz, 2008)), the genetic data shall be summarized 
here in brief as both the NOS1 and the NOS1AP genes have been described as functional 
candidates for schizophrenia. Regarding NOS1, the majority of functional candidate gene 
studies yielded positive results, although the ethnicity of the investigated samples as well as 
the tested SNPs were quite heterogeneous. Only one study (Fallin et al., 2005), conducted in 
Ashkenazi Jews, employed a family-based design and yielding positive results. The first case-
control study was published in 2002 and tested a potentially functional SNP in the 3’UTR in a 
sample of 215 Japanese schizophrenic patients (Shinkai et al., 2002), also with positive 
outcome. Subsequently, our group conducted a mutation analysis, qRT PCR and haplotype 
analysis in Caucasian patients suffering from schizophrenia arguing that a functional 
promoter SNP (rs41279104), resulting in decreased expression of a reporter gene in cell 
culture experiments (Saur et al., 2004), is associated with disease (Reif et al., 2006a). Since 
then, six more case-control association studies on schizophrenia and NOS1 were published in 
total (Cui et al., 2010; Nicodemus et al., 2010; Okumura et al., 2009; Riley et al., 2010; Tang 
et al., 2008; Wang et al., 2012). Four of those came from Asian populations (two Chinese 
(Tang et al., 2008) and two Japanese (Cui et al., 2010; Okumura et al., 2009)), with mixed 
results: while Cui and associates replicated the positive finding on rs41279104 (and also 
provided evidence for reduced NOS-I expression on the protein level in BA9 - part of the 
dorsolateral prefrontal cortex - for risk allele carriers), Okumura could not, although two 
other NOS1 SNPs were significant (but did not survive correction for multiple testing). The 
same was true for the study by Wang (Wang et al., 2012) in China, where a SNP in intron 2 of 
NOS1 was only nominally significant. In contrast, the other study from China (Tang et al., 
2008) found significant evidence for an association of NOS1 (5’UTR and intron 2) with 
schizophrenia as well. One Irish population did not provide evidence for an association of 
NOS1 with schizophrenia, although only 4 SNPs were tested and did not include the 
previously significant rs41279104 (Nicodemus et al., 2010). Taken together, these 
association studies rather argue for an association of the 5’ end of NOS1 – especially the 
promoter region – with schizophrenia. Not surprisingly, a small Chinese study (n=198) on a 
CA-dinucleotide repeat in the 3’UTR of the gene yielded negative results (Liou et al., 2002). 
However, NOS1 is not only a functional candidate gene, but also a positional 
candidate gene as the NOS1 locus is a hot spot for schizophrenia in linkage analyses (an 
overview can be gathered from Fig. 1 in (Reif et al., 2006)). Yet not only linkage studies, but 
also genome-wide association studies (GWAS) have suggested NOS1 as a schizophrenia risk 
gene; with rs6490121 located in intron 10 of NOS1 yielding a p-value of 9.82 × 10–6 in the 
study by O’Donovan and colleagues (O'Donovan et al., 2008), thus being the third best hit of 
the GWAS. A follow-up of this SNP in an Irish sample of 1,021 cases did not yield positive 
results (Riley et al., 2010), however. 
The most promising association findings were followed up in endophenotype 
experiments. The functional promoter SNP rs41279104 was tested in studies using event-
related potentials and functional near-infrared spectroscopy (Reif et al., 2006; Reif et al., 
2011), providing evidence for a prefrontal deficit in risk allele carriers. In addition, Kawohl 
and associates (Kawohl et al., 2008) demonstrated that rs41279104 risk allele carriers had 
decreased loudness dependence of auditory evoked potentials, which is a functional marker 
of serotonergic transmission, arguing for a connection between the NO and serotonin 
systems as also shown on the protein and the neuronal network (Kiss and Vizi, 2001) level. 
Also, the GWAS risk SNP rs6490121 was shown to be functional in respect to general 
intelligence, working memory and visual sensory processing as measured by the 
electroencephalogram event-related P1 response (Donohoe et al., 2009; O'Donoghue et al., 
2012). Most of these effects could also be observed in healthy controls, and not only 
patients. Also, healthy risk allele carriers had a reduction in ventromedial prefrontal grey 
matter volume and altered activation of this and other structures during working memory 
tasks (Rose et al., 2012).  
In addition to NOS1, the NOS1AP gene has consistently been suggested to be 
associated with schizophrenia. As a finding from linkage studies on Canadian families (having 
Celtic or German background), suggesting the NOS1AP locus chromosome 1q22 as a linkage 
hot spot, this gene came into focus in psychosis research as fine-mapping could narrow the 
critical region to this gene (Brzustowicz et al., 2004). In the following years, this group has 
provided further evidence that NOS1AP is implicated in schizophrenia pathogenesis, 
stemming from family-based genetic studies and suggesting a functional variant (Wratten et 
al., 2009), although another group examining a UK sample argued that rather the 
neighboring gene UHMK1 underlies the linkage peak (Puri et al., 2007; Puri et al., 2006). 
Following up the studies of Brzustowicz and colleagues, both positive (Kremeyer et al., 2009; 
Miranda et al., 2006; Zheng et al., 2005) as well as negative (Fang et al., 2008; Nicodemus et 
al., 2010; Nicodemus et al., 2008) family-based and case-control studies were published. In 
addition, a mutation analysis suggested that rare coding variants in NOS1AP underlie 
obsessive-compulsive disorder and autism (Delorme et al., 2010). Furthermore, NOS1AP was 
suggested to play a role in antipsychotic-mediated QTc prolongation (Aberg et al., 2010) 
which is not surprising given its highly significant influence on the QTc interval.  
Due to these repeatedly described and promising associations of both NOS1 and 
NOS1AP (as well as three other genes coding for components of the glutamatergic synapse 
which interact with NOS-I in a protein-protein manner, namely DYNLL1, RASD1 and SYN2) 
with schizophrenia, we here tested in three samples whether we can confirm these findings 
and whether NOS1 and NOS1AP interact in an epistatic manner, which is expected due to 
their physical interaction. We also aimed to back up this data by meta-analytic approaches 
as well as bioinformatic analysis, and finally we attempted to replicate the functionality of 
NOS1 rs41279104 in human post-mortem brain tissue.  
Experimental Procedures 
Genotyped samples  
We here extended a previously described sample (Reif et al., 2006) by genotyping 
more markers and adding a further 75 patients suffering from schizophrenia. In brief, a total 
of 270 unrelated patients (thereof 54% males; mean age 41±13 years) from the Lower 
Franconia area in Germany participated, which were ascertained as inpatients at the 
Department of Psychiatry and Psychotherapy, University of Würzburg. None of the subjects 
remitted completely during the course of the disease and thus the sample consists entirely 
of patients suffering from chronic schizophrenia, i.e. it is selected for severe cases; 
diagnostic evaluation was made by at least two experienced psychiatrists. The control 
sample consisted of 720 individuals (thereof 52% males; mean age 33±11 years), all healthy 
blood donors, hospital staff and volunteers stemming from the same catchment area as the 
patient group. A further 101 patients with schizophrenia were recruited from care centers in 
Umeå, Northern Sweden. All patients had at least two discharge diagnoses of schizophrenia 
as well as a life-time diagnosis of schizophrenia. Final diagnosis was determined by the 
consensus of two research psychiatrists, and only patients for whom full consensus was 
reached were included. Mean age of patients at the time of DNA sampling was 50 years. 
Control subjects (n=168, mean age 59 years) were recruited from a random population 
prospective longitudinal study in Umeå, and none of the controls had a life-time diagnoses 
of schizophrenia or any other psychotic disorder. The sex ratio was similar in the two 
samples: the schizophrenic patients consisted of 52% males, and the control subjects of 45% 
males. Finally, 270 unrelated psychiatric patients (thereof 84 females) from Spain were 
included (mean age 39±11 years). Patients came from the psychiatric in-patient and out-
patient units of the Mental Health Service 4 of the Clinical Hospital, University of Valencia, 
Spain. The retrospective clinical data collected from each patient were compared with the 
information provided from previous clinical reports and family members. Diagnoses were 
confirmed by a consensus meeting with the treating psychiatrist and one of the psychiatrists 
of the research group. Patients also had a minimum one-year evolution of the illness and 
were on antipsychotic treatment at evaluation time. The control group consisted of 360 
healthy unrelated subjects of Spanish origin (thereof 124 females) with no history or familiar 
background of mental disorders (mean age 37±15 years).  
All of the patients suffered from schizophrenic disorders according to ICD-10 
(Germany) or DSM-IV (Spain, Sweden) criteria. None of the subjects showed significant 
neurological comorbidity, epilepsy, mental retardation, or other somatic disorders 
suggesting organic psychiatric disorder. Patients with substance-induced psychotic episodes 
were excluded from the study as well. Both patients as well as controls were of Caucasian 
ethnicity. Only patients and volunteers who gave written informed consent after oral as well 
as written explanation about scope and aim of the investigation were enrolled in the study. 
All studies complied with the Declaration of Helsinki and were approved by the respective 
local ethical committees; informed consent was obtained from all participating subjects. 
Genotyping and SNP selection 
SNPs in the NOS1AP and NOS1 regions have previously been examined in case-
control studies of schizophrenia {Brzustowicz, 2004 #252; Cui, 2010 #715; Nicodemus, 2010 
#747; Okumura, 2009 #749; Puri, 2006 #755; Tang, 2008 #676; Zheng, 2005 #299}. To enable 
meta-analysis, we have selected 13 NOS1AP SNPs (rs1572495, rs1538018, rs945713, 
rs1415263, rs4306106, rs3924139, rs4145621, rs1508263, rs3751284, rs7521206, rs905721, 
rs348624, rs1964052) and 8 NOS1 SNPs (rs3782206, rs3837437, rs499776, rs3782219, 
rs3782221, rs1879417, rs4767540, rs41279104) from previously published studies for 
further genotyping. Furthermore, SYN2 SNPs have previously been analyzed in a family-
based setting in schizophrenia {Saviouk, 2007 #784}; we have selected seven polymorphisms 
(rs598747, rs598704, rs308969, rs931676, rs3817004, ss35528972, rs3755724) for 
genotyping from this study, however, we did not carry out a meta-analysis due to the 
different study types. For RASD1 and DYNLL1, no publications reported on an associations 
with schizophrenia; we therefore selected a set of eight representative SNPs (RASD1: 
rs4924755, rs711352, rs2232841, rs2232838; DYNLL1: rs12857, rs3916065, rs787828, 
rs9788155) capturing the common allelic variation in these genes including the 5 kb 
upstream and 3 kb downstream regions with minimal genotyping effort. For SNP selection, 
we used the Tagger function implemented in Haploview 4.2 using HapMap CEU as reference 
population. Together, this resulted in 36 selected SNPs. Genomic DNA of all participants was 
extracted from venous blood by the standard methods. Subsequent SNP genotyping was 
performed with Sequenom’s MassArray® system using the iPlex® chemistry following the 
MassArray® iPlex® standard operation procedure. Primer sequences can be found in 
Supplementary Table 1. 
NOS1 mRNA quantification 
 For quantification of total NOS1 RNA expression in human brain, a sample of human 
post-mortem brains, with post-mortem intervals (PMI) from 28 h up to 111 h (mean PMI 
54.84 ± 16.63) was obtained from the Medical Research Council (MRC) Sudden Death Brain 
and Tissue Bank, Edinburgh. From 76 deceased individuals, aged between 16 and 74 (N = 76; 
female = 18, male = 58; mean age 48.55 ± 12.79), DNA and RNA from three brain regions 
(amygdala, forebrain and midbrain) were isolated, using the MELTTM Total Nucleic Acid 
Isolation System (Applied Biosystem, AM Foster City, 1983) and stored at -80°C until use. 
RNA quality, measured with a Bioanalyzer (Agilent), revealed RNA integrity numbers (RIN) 
ranging from 1.5-2.0. Total RNA from forebrain, midbrain and the amygdala of human post-
mortem brains was reversely transcribed by using the iScript™ cDNA synthesis kit (Bio-Rad, 
München, Germany) on 1 µg total RNA of each sample. cDNA was quantified in triplicates on 
a Bio-Rad CFX384 real-time PCR detection system, by applying the iQ™ SYBR green supermix 
from Bio-Rad and NOS1-specific QuantiTect Primer (QT00043372) from Qiagen in a 10 µl 
reaction volume. PCR conditions were 5 min at 95°C, 40 cycles of 10 s at 95°C, 30 s at 60°C, 
followed by a melting curve analysis with a gradient of 65°C to 95°C of 0.5°C per 5 s. Raw 
NOS1 expression data were normalized by mean efficiencies obtained from LinRegPCR and 
normalization factors based on the three (of six investigated) most stable housekeeping 
genes (GAPDH, TBP, SDHA), defined by the geNorm software. To investigate the influence of 
rs41279104 on gene expression, we carried out ANOVAs and post-hoc t-tests on normalized 
logarithmized NOS1 expression values in genotypic and dominant models. Allele-specific 
changes of gene expression were examined with linear regression.  
Statistical Analysis 
Statistical analysis of genotype data was performed with PLINK version 1.07 and R 
version 2.10. Quality control required polymorphic variants with a minor allele frequency 
(MAF) above 1%, a call rate (CR) above 90% and that overall genotype frequencies did not 
deviate from Hardy-Weinberg equilibrium (HWE; χ2 HWE p-value ≥ 0.05); thirty variants 
complied with these inclusion criteria. In all three samples (i.e., German, Swedish and 
Spanish), rs3837437 yielded a MAF below 0.01; rs2232841, rs2232838, rs3916065, 
rs4145621, rs931676 did not reach the CR threshold and were thus excluded from further 
analysis. 
Single-marker associations were calculated by comparison of allele and genotype 
counts using Fisher´s exact tests. Calculations were performed in each sample separately to 
account for ethnic discrepancies; for joint analyses, samples were subjected to meta-analysis 
(see below). For multi-marker association, haplotype blocks were defined according to the 
solid spine method; inferred haplotype counts in groups were compared with 1-degree-of-
freedom χ2 tests. P-values from single marker and haplotype analyses were separately 
adjusted for the number of tests performed in each sample using the conservative 
Bonferroni correction. In the combined analysis of all three samples, we achieve a power of 
66% and 62% to detect nominal significant SNPs and haplotypes, respectively, conveying a 
relative risk of 1.4 to develop schizophrenic disorder assuming a co-dominant model and a 
MAF of 0.05 (Power for Genetic Association version 2.0).  
Meta-analysis 
To obtain maximal information regarding the NOS1 and NOS1AP variants tested in 
the present study, we performed a meta-analysis of the data (significant SNPs only) 
presented here together with all previous case-control genotyping efforts. To this end, a Pub 
Med search was carried out using the keywords “(NOS1AP OR CAPON) AND schizophrenia” 
as well as “NOS1 AND schizophrenia”, to identify all genetic studies on NOS1AP (n=24 
retrieved studies) or NOS1 (n=42 retrieved) and schizophrenic disorders. Titles and abstracts 
were scrutinized to exclude non-genetic studies, reducing the number of included studies to 
15 for NOS1AP and 15 for NOS1. Of those, 9 studies on NOS1AP (Brzustowicz et al., 2004; 
Costain et al., 2010; Fang et al., 2008; Greenwood et al., 2011; Husted et al., 2010; Kremeyer 
et al., 2009; Miranda et al., 2006; Nicodemus et al., 2008; Wratten et al., 2009) and one on 
NOS1 (Fallin et al., 2005), presented family-based, but not case-control data and were 
therefore not integrated in the meta-analysis for methodological reasons. The remaining 
studies on NOS1AP (n=6; (Aberg et al., 2010; Delorme et al., 2010; Nicodemus et al., 2010; 
Puri et al., 2007; Puri et al., 2006; Zheng et al., 2005)) and NOS1 (n=14; (Cui et al., 2010; 
Donohoe et al., 2009; Kawohl et al., 2008; Nicodemus et al., 2010; O'Donoghue et al., 2012; 
Okumura et al., 2009; Reif et al., 2006; Reif et al., 2011; Riley et al., 2010; Rose et al., 2012; 
Shinkai et al., 2002; Silberberg et al., 2010; Tang et al., 2008; Wang et al., 2012)) reported on 
case-control association data and were scrutinized in greater detailed. For NOS1AP, two and 
for NOS1, 11 further studies had to be excluded from meta-analysis for the following 
reasons. For the NOS1AP gene: (Aberg et al., 2010) reported on cases only, while (Puri et al., 
2007) investigated SNPs that were not included in our genotyping battery. For the NOS1 
gene: (Kawohl et al., 2008; O'Donoghue et al., 2012; Rose et al., 2012) analysed exclusively 
healthy participants. (Donohoe et al., 2009; Nicodemus et al., 2010; Riley et al., 2010) and 
(Shinkai et al., 2002) only presented data on SNPs which have not been genotyped for the 
present study; no SNP data could be obtained from the study of (Wang et al., 2012); and the 
study by (Silberberg et al., 2010) was excluded because of the rather small sample size 
(n=26) precluding meaningful interpretation of the data. Finally, (Reif et al., 2011) and (Reif 
et al., 2006), were excluded because the case samples of both studies overlapped with the 
sample described here (while the control sample was extended more than two-fold). 
Therefore, four studies on NOS1AP (nmax
cases=2406) and three studies on NOS1 
(nmax
cases=2006) were meta-analytically treated together with the data presented in this 
report yielding a sample power of 99% for NOS1AP and 98% for NOS1 to detect SNPs 
associations, based on a relative risk of 1.4 and a MAF of 0.05.  
The calculations for meta-analysis were performed using R version 2.10 along with 
the package metaphor version 0.5-7 using the “rma” command. For meta-analysis, we 
calculated odds ratios (ORs) as a measure for effect size and applied the Q-statistic to assess 
heterogeneity therein. Inconsistency across studies was quantified with the I^2 metric 
(I^2=Q-df/Q). The joint OR was determined as the weighted average of effect sizes entering 
the meta-analysis. When no heterogeneity was detected in the effect sizes, we applied fixed-
effects models, where the weights correspond to the inversed variances of the study ORs. In 
the presence of significant (p<0.05) heterogeneity, we applied random-effects models. Here, 
weights are initially calculated as in the fixed-effects model, but are then down-weighted by 
the degree of variance of effect sizes. Visual inspection of Funnel plots (Supplementary 
Figure 1) did not argue for the presence of publication bias. 
Interaction analysis 
Interaction analyses were calculated with PLINK version 1.07. SNPs with Bonferroni-
resistant association and/or p<0.05 in the meta-analysis (see below) were subjected to 
pairwise interaction analysis, examining the genetic effect of one SNP in dependence of the 
genotype of the other SNP. The search for such epistatic effects was performed in two 
modes, namely in the whole case-control sample with the command “fast-epistasis” and in 
the case-only study subset by use of the additional command “case-only”. Calculations were 
performed separately in each study sample as well as in the combined sample to increase 
power. 
Bioinformatic analysis 
Analyses of SNPs were performed with tools that are contained in the GenEpi toolbox 
(http://genepi_toolbox.i-med.ac.at/). Annotation of SNPs in linkage disequilibrium (LD) with 
associated SNPs in a distance of 500 kb was retrieved from the SNAP website version 2.2. 
Differential transcription factor binding site (TFBS) predictions were made using the web-
based tool MatInspector version 2.1. To indicate a SNP´s possible influence on splice 
junctions such as predictions of splice sites as well as binding sites for splicing regulatory 
elements (SREs, including Intronic Splicing Enhancer (IES) and Intronic Splicing Silencer (ISS)), 
the Human Splicing Finder software (HSF) version 2.4.1 was used. 
Results 
Single marker analysis 
We calculated case-control single marker analyses for each of the three samples 
separately due to their different geographic origin. Genotypic, allelic as well as dominant 
models were used (Table 1). Of the 12 SNPs in NOS1AP, six were nominally associated in at 
least one of the samples, with rs945713 surviving Bonferroni correction in the German 
sample. In the Swedish sample, this SNP displayed a trend towards association (p=0.064). 
Three of the seven examined NOS1 SNPs were nominally associated in at least one sample; 
rs499776 survived Bonferroni correction in the Swedish sample and was nominally 
associated in the two other samples. No SNP associations were observed in SYN2, DYNLL1 
and RASD1.  
Haplotype analysis 
LD plots of the analyzed NOS1AP and NOS1 regions are displayed in Figure 1. In the 
haplotype analysis, we found two associated haplotypes in NOS1AP’s block 1 in the Swedish 
sample (Table 2) containing SNPs that all were significant in the single marker analysis in this 
sample. Furthermore, in the German sample, a NOS1 haplotype containing rs4767540 and 
rs41279104 was nominally significant (p=0.028), although not on the Bonferroni-adjusted 
level.  
Meta-analysis 
All NOS1AP (Table 3) and NOS1 (Table 4, Figure 2) SNPs genotyped in the present 
study were subjected to a meta-analysis, thereby also incorporating results from previously 
published studies. The maximum number of investigated patients was 2,466 for NOS1AP and 
2,006 for NOS1, respectively. Six NOS1AP SNPs displayed significantly heterogeneous genetic 
effects, but no significant pooled effect size was determined with random effects models 
(Tables 3 and 4). In contrast, effect sizes of all examined NOS1 SNPs were homogeneous; 
three thereof conveyed a significant pooled genetic effect (Table 4, Figure 2): rs3782206, 
rs499776 and rs41279104, with the latter yielding the strongest signal conveying odds ratios 
of 1.29 (dominant model) and 1.25 (allelic model), respectively. 
Interaction analysis 
Epistatic effects were tested in pairwise combinations of SNPs rs945713 and 
rs499776 as well as rs3782206 and rs41279104, of which meta-analytic treatment predicted 
significant genetic effect sizes (see above). Neither the separate nor the combined case-
control samples revealed a significant interaction. However, when considering cases only, a 
significant interaction between rs945713 and rs41279104 was found in the German 
(p=0.004) and the combined sample (p=0.012).  
Assessment of rs41279104 function on mRNA level 
Allele-specific mRNA quantification in human post-mortem prefrontal cortices 
revealed a significant linear reduction (beta=-0.087) of NOS1 expression values per 
minor/risk T allele of rs41279104. Differential expression by genotype group showed 
significant association in the prefrontal cortex (ANOVA p=0.036, post hoc t-test p=0.012). 
NOS1 expression in the amygdala or the midbrain was not found to be influenced by 
rs41279104 (data not shown).  
Bioinformatic analysis of rs945713, rs3782206, rs499776 and rs41279104 
For functional prediction of rs945713, rs3782206, rs499776 and rs41279104, high LD 
proxies (r2 ≥ 0.9 and D´=1) were searched within a distance of 500 kb (Suppl. Table 2). This 
search resulted for the NOS1AP variant rs945713 in six high LD proxies, all located in the 
second intron of the gene. The three NOS1 SNPs rs41279104, rs499776 and rs3782206 had 
altogether 33 proxies of which six were located in the promoter region, four in the first and 
23 in the second intron of NOS1. For the promoter SNP rs41279104, which was found to be 
most strongly associated with schizophrenia, no clear function was predicted, but the minor 
alleles of its four proxies rs900622, rs12316771, rs34731287 and rs12312120 replace six 
transcription factor binding sites (TFBS) for HOXC9, MSX1, ELF5, DLX1, SPZ1 and MAZR by 
two new binding sites for E2F and HMX3. As all predicted TFBS are expressed in the nervous 
system, we predict rs41279104 together with its four promoter proxies to have an effect on 
NOS1 expression, which is in line with the significant differential mRNA level in forebrain 
(see previous section). 
Moreover, we observed differences in counts of predicted splicing regulatory 
elements between major and minor alleles of associated intronic SNPs and their proxies. 
Specifically, the risk (minor) allele of the NOS1AP variant rs945713 replaces binding sites for 
two splicing enhancers (SE) by one splicing inhibitor (SI). Furthermore, the NOS1 associated 
SNP rs3782206 and its proxies create three SI and 11 SE binding sites, but erase 6 SI and 16 
SE binding sites in the presence of the minor risk allele (suppl. Table 1). Finally, the 
protective minor allele of rs499776 along with its two proxies rs570234 and rs1681506 
decrease the predisposition towards schizophrenia by deletion of three binding sites for SEs 
(see Suppl. Table 2), which may repress alternative splicing of NOS1 transcripts.  
Discussion 
  Molecular effects of risk alleles 
By investigating three discovery samples from Germany, Sweden and Spain, followed 
by meta-analysis of these and published data, we provide evidence that variants of genes 
coding for components of the NO system at the glutamatergic post-synapse interact to 
increase the risk towards schizophrenia. While neither RASD1, DYNLL1 (which have not yet 
been specifically tested before) nor SYN2 (which had some prior evidence; (Saviouk et al., 
2007)) gave a significant signal, SNPs in NOS1AP and NOS1 did; both genes in the present 
case-control studies and the latter also in the meta-analysis. These SNPs have been 
previously suggested to contribute to schizophrenia liability, and most interestingly, they 
also interacted in increasing disease risk. Odds ratios were in the expected range for 
common variants, although the NOS1 promoter polymorphism rs41279104 conveyed a 
relatively high risk with an OR=1.3. Most interestingly, following initial studies arguing for an 
effect of this SNP on reporter gene expression in heterologous cell systems, we could extend 
this data here by showing that the risk allele resulted in lower NOS1 expression in the 
prefrontal cortex which is in line with data showing reduced NOS-I immunohistochemical 
staining in the prefrontal cortex in risk allele carriers (Cui et al., 2010). To clarify molecular 
function of rs41279104 and six high LD proxy SNPs on NOS1 expression in greater detail, we 
used several in silico approaches which revealed that the SNPs’ minor alleles replace 
putative binding sites for transcription factors that are known to be expressed in the 
prefrontal cortex; this provides a possible mechanism how rs41279104 by means of its 
proxies may influence NOS1 expression.  
In contrast to our results, a study by Silberberg et al. (2010) did not detect any 
changes in NOS1 expression in rs41279104 carriers. Importantly, in the study by Silberberg 
et al. (2010) samples from both healthy and schizophrenic subjects were used, with 
increased NOS1 expression in patients with schizophrenia, regardless of genotype. In 
contrast, samples analyzed in our study were only obtained from healthy subjects. 
Therefore, it is possible that in the Silberberg et al. (2010) study increased NOS1 expression 
in schizophrenic patients is masking a possible reduction in NOS1 expression caused by 
rs41279104. Alternatively, this might be due to a mere power problem, inherent to this kind 
of studies where only a few risk allele carriers can be tested and overall sample size is 
limited. Moreover, this could be a brain region-specific effect, or different LD structure in the 
tested population. Nevertheless we are confident that we are indeed picking up true 
molecular consequences of rs41279104 at least in Caucasians. 
Interestingly, a number of studies have suggested that NO plays an important role in 
the biochemical and behavioral effects of the psychotomimetic NMDA-receptor antagonist 
phencyclidine (PCP) (Palsson et al., 2010), and a recent finding demonstrates that prefrontal 
NO/sGC signaling is important for the effects of PCP (Fejgin et al., 2008). However, preclinical 
and clinical data underscores that both an abnormal increase and a decrease in NO signaling 
can underlie schizophrenia-like deficits. Taken together, the present and previous findings 
indicate a dysregulated NO system as part of the pathophysiology of schizophrenia. Hence, 
pharmacological manipulation of NO activity may be a fruitful approach when trying to 
alleviate cognitive dysfunctions in schizophrenia. 
 NOS-I – NOS1AP interaction as a molecular mechanism in schizophrenia 
NOS1 and NOS1AP tightly interact on the protein level and both proteins have 
repeatedly been associated with schizophrenia not only on the genetic level, as outlined 
above, but also coming from other lines of research. The NOS I protein carries an amino-
terminal PSD 95/Discs large/Zonula occludens 1 (PDZ)-domain followed by a β finger 
encoding a PDZ-motif (-ETTF-). The PDZ-motif of NOS I interacts with the PDZ2 domain of 
PSD 95/ 93, thereby anchoring NOS I to the postsynaptic density and allowing proximity of 
NOS-I to NMDA receptors. This allows activity-dependent NO production by NOS-I by 
Calcium-influx through NMDA receptors. The PDZ-domain of NOS-I directly interacts with 
NOS1AP (Jaffrey et al., 1998), which alters the subcellular localization of NOS-I away from 
the post synaptic density, by binding to RASD1 (Fang et al., 2000) or Synapsin 1 (Jaffrey et al., 
2002). The binding of NOS1AP to NOS-I directly competes with the interaction between NOS-
I and PSD-95/-93, and overexpression of NOS1AP was shown to reduce the interaction 
between NOS-I and NOS1AP (Jaffrey et al., 1998). Blocking the PDZ-domain of NOS-I with 
small molecule inhibitors has been suggested as a possible therapeutic approach in the 
treatment of depression, a hypothesis that is supported by preclinical evidence (Doucet et 
al., 2013). Since we show that expression levels of NOS-I are reduced in rs41279104 risk 
allele carriers, and since elevated expression of NOS1AP interfering with post-synaptic 
targeting of NOS-I (Jaffrey et al., 2002; Jaffrey et al., 1998) is elevated in schizophrenic 
patients (Xu et al., 2005), a comparable approach (i.e., blocking NOS-I – NOS1AP interaction 
with small molecules) might provide a feasible strategy for treatment at least in patients 
carrying this risk allele. In this context, it is also interesting to note that another SNP that was 
associated with schizophrenia in a family-based study (and therefore not included in our 
meta-analysis) produced elevated NOS1AP promoter activity in human cell lines (Wratten et 
al., 2009). 
 Human functional consequences of comprised prefrontal NOS functioning 
Being stimulated by findings in Nos1 knockout mice that feature cognitive deficits 
(Zoubovsky et al., 2011), studies on the differential influence of NOS1 polymorphisms on 
human cognition provided compelling evidence for a role of this gene in prefrontal function. 
This was not only shown in patients, but rather also in healthy controls outlined in this 
section. For instance, we demonstrated (Reif et al., 2006) that the rs41279104 risk allele is 
associated with fewer errors and a reduced P300 latency in a continuous performance test 
(CPT) and argued that this polymorphism, leading to reduced NOS1 expression in the 
prefrontal cortex, might raise efficiency for executive functions by reducing the signal to 
noise ratio. This is achieved via lower NO levels, which will result in less activation of 
neighboring neurons (a smaller “NO cloud”, see (Kiss and Vizi, 2001)). We later reported an 
influence of another NOS1 promoter polymorphism (NOS1 ex1f-VNTR) on the same task. 
Performance during the CPT was measured with EEG and the resulting No-Go centroid, 
associated with activation of the anterior cingulate gyrus (ACC), was localized significantly 
more posterior in subjects carrying the risk allele of NOS1 ex1f-VNTR, which also leads to 
lower NOS1 expression. This was interpreted as a diminished ACC activation in risk allele 
carriers leading to impaired medial prefrontal functioning. This assumption was 
corroborated by data showing brain differential activation in NOS1 ex1f-VNTR risk allele 
carriers in a working memory and a stop-signal task (Kopf et al., 2012). 
Furthermore, another NOS1 polymorphism (rs6490121) was associated with working 
memory as homozygous carriers of the risk allele performed more poorly (Donohoe et al., 
2009). This effect was also observed for verbal IQ measures. That same SNP was found to be 
associated with lower P1 visual evoked potentials elicited by a spatial working memory task 
in a high density EEG study (O'Donoghue et al., 2012). Carriers of the risk allele showed 
significantly lower P1 responses than non-carriers, pointing to a function of NOS1 even in 
early sensory processing. Finally, Rose and colleagues (Rose et al., 2012) used voxel based 
morphometry and showed that grey matter volume in the ventromedial prefrontal cortex is 
significantly reduced in risk allele carriers. They also conducted a spatial working memory 
test and demonstrated increases in the activation of fronto-parietal working memory 
networks and a failure to disengage regions of the default mode network for risk allele 
carriers. Taken together, present data strongly suggests that genetic variation in NOS1 – 
mainly underlying reduced expression of the gene – leads to compromised cognitive 
functioning and differential prefrontal brain activity also in healthy individuals. This influence 
on neurocircuitry exerted by NOS1 might well underlie the association of this gene with 
schizophrenia, where cognitive deficits are amongst the core symptoms of the disease.  
 Limitations 
A few limitations have to be considered in the interpretation of our data. First, the 
power of the discovery samples to detect effects was intermediate which might compromise 
the interaction analysis; as the meta-analytic study was well-powered, we aimed to 
overcome this issue. However, meta-analysis did not cover all previously significant SNPs so 
that further large-scale studies should incorporate a more extensive SNP panel also allowing 
for gene-based analyses. Ethnic differences in the investigated samples have also been taken 
into account, as different LD structures in different populations might obscure the linkage 
with “true” underlying risk variants. On the pathophysiological level, our data is at odds with 
three other studies arguing for unchanged (Cui et al., 2010) or even increased (Baba et al., 
2004; Silberberg et al., 2010) NOS1 expression in schizophrenia. As the study by Cui and 
associates also found reduced NOS1 expression in risk allele carriers, one might rather 
assume that reduced NOS1 expression is not to be found in schizophrenia as a whole but 
rather there is a genetically distinct schizophrenia sub-group that is characterized by 
compromised NO signaling, while other sub-groups might display compensatory up-
regulation of NOS1. Such a genetic dissection of schizophrenia might lead to more 
meaningful insights into disease mechanisms than rather treating the disorder on the 
aggregate level which obscures biological findings. 
Outlook 
Taken together, from our data it appears that reduction of NOS-I expression as a 
consequence of genetic variation and especially in conjunction with increased NOS1AP 
expression poses a risk factor for the development of schizophrenia. Further downstream, 
reduction of PSD-95/-93 associated NOS-I and consequently compromised NMDA – NO 
signaling might be the converging mechanism underlying at least some forms of psychosis. 
This puts NO pathways in the glutamatergic post-synapse central to the development of this 
disorder and calls for innovative pharmacological targeting of this protein complex. In line 
with these assumptions, a recent study demonstrated that a single dose of an NO donor was 
able to significantly reduce schizophrenia symptoms rapidly (4h) after infusion, and that this 
effect was detectable for almost 4 weeks (Hallak et al., 2013). Thus, genetic data informing 
about reduced NOS1 expression might well provide information on which patients would 
best benefit from such an intervention in the sense of personalized medicine. According 
studies to either corroborate or reject this hypothesis might provide valuable insights in the 
role of NO in schizophrenia.  
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Figures  
 
Figure 1: Linkage disequilibrium (LD) plots of NOS1AP (A) and NOS1 (B). LD is displayed as D’ 
Haplotype blocks as defined by the solid spine method.  
 
 
Figure 2: Forest plots of NOS1AP rs3782206 dominant and allelic model (A), NOS1 rs499776 
dominant and allelic model (B) and NOS1 rs41279104 dominant and allelic model (C) 
 
Table 1:  Association results for examined SNPs along with their chromosomal position, minor/major alleles, genotype and allele counts for cases and controls, 
the nominal p-value of Fisher´s exact tests of a genotypic, allelic and dominant model and the respective Bonferroni-corrected p-values for the German, Swedish 
and Spanish samples. Bold indicates SNPs with at least one significant p-value (p<0.05) in one or more of the three calculated models. Chromosomal positions 
were given according to the latest NCBI Genome assembly GRCh37.p5. 
    
German sample Swedish sample Spanish sample 
 
Chromosomal Allele 
 
Number of Genotypes Nominal Bonferroni Number of Genotypes Nominal Bonferroni Number of Genotypes Nominal Bonferroni 
SNP Position (bp) (d/D) Association Model 
Controls 
(n=720) 
Cases 
(n=270) 
P-value P-value 
Controls 
(n=168) 
Cases 
(n=101) 
P-value P-value 
Controls 
(n=360) 
Cases 
(n=270) 
P-value P-value 
NOS1AP (Capon); Chromosome 1: 
rs1572495 162099301 T/C Genotypic n(dd/dD/DD)  7/108/587 3/39/213 0,936 1 1/22/140 0/11/89 0,735 1 2/56/284 4/41/223 0,552 1 
   
Allelic n(d/D) 122/1282 45/465 0,927 1 24/302 11/189 0,474 1 60/624 49/487 0,840 1 
   
Dominant n(dd+dD/DD) 115/587 42/213 1,000 1 23/140 11/89 0,571 1 58/284 45/223 1,000 1 
rs1538018 162130481 C/G Genotypic n(dd/dD/DD)  -- -- -- -- 8/57/90 8/35/54 0,620 1 -- -- -- -- 
   
Allelic n(d/D) -- -- -- -- 73/237 51/143 0,524 1 -- -- -- -- 
   
Dominant n(dd+dD/DD) -- -- -- -- 65/90 43/54 0,794 1 -- -- -- -- 
rs945713 162135670 C/T Genotypic n(dd/dD/DD)  102/339/257 57/130/73 0,006 0,167 36/71/49 12/48/37 0,101 1 63/162/118 49/139/79 0,413 1 
   
Allelic n(d/D) 543/853 244/276 0,002 0,048 143/169 72/122 0,064 1 288/398 237/297 0,415 1 
   
Dominant n(dd+dD/DD) 441/257 187/73 0,012 0,326 107/49 60/37 0,278 1 225/118 188/79 0,222 1 
rs1415263 162166043 T/C Genotypic n(dd/dD/DD)  107/333/262 43/134/78 0,155 1 38/79/44 10/51/38 0,012 0,353 71/162/108 50/138/77 0,532 1 
   
Allelic n(d/D) 547/857 220/290 0,102 1 155/167 71/127 0,006 0,191 304/378 238/292 0,954 1 
   
Dominant n(dd+dD/DD) 440/262 177/78 0,056 1 117/44 61/38 0,074 1 233/108 188/77 0,534 1 
rs4306106 162171994 A/G Genotypic n(dd/dD/DD)  36/217/442 14/93/151 0,337 1 16/64/75 3/35/59 0,042 1 29/139/175 16/118/132 0,419 1 
   
Allelic n(d/D) 289/1101 121/395 0,210 1 96/214 41/153 0,018 0,536 197/489 150/382 0,848 1 
   
Dominant n(dd+dD/DD) 253/442 107/151 0,154 1 80/75 38/59 0,069 1 168/175 134/132 0,744 1 
rs3924139 162192112 G/A Genotypic n(dd/dD/DD)  84/325/288 40/122/97 0,303 1 33/79/45 7/49/41 0,004 0,128 65/154/126 41/139/87 0,179 1 
   
Allelic n(d/D) 493/901 202/316 0,149 1 145/169 63/131 0,003 0,087 284/406 221/313 0,953 1 
   
Dominant n(dd+dD/DD) 409/288 162/97 0,299 1 112/45 56/41 0,029 0,884 219/126 180/87 0,347 1 
rs1508263 162279509 A/G Genotypic n(dd/dD/DD)  139/358/199 46/119/80 0,490 1 34/68/51 25/49/21 0,166 1 69/176/97 30/142/94 0,007 0,187 
   
Allelic n(d/D) 636/756 211/279 0,317 1 136/170 99/91 0,116 1 314/370 202/330 0,006 0,155 
   
Dominant n(dd+dD/DD) 497/199 165/80 0,255 1 102/51 74/21 0,063 1 245/97 172/94 0,078 1 
rs3751284 162313735 A/G Genotypic n(dd/dD/DD)  90/307/298 29/116/110 0,825 1 30/65/67 8/54/38 0,022 0,653 32/168/136 33/111/123 0,104 1 
   
Allelic n(d/D) 487/903 174/336 0,744 1 125/199 70/130 0,457 1 232/440 177/357 0,625 1 
   
Dominant n(dd+dD/DD) 397/298 145/110 0,941 1 95/67 62/38 0,606 1 200/136 144/123 0,185 1 
rs7521206 162330927 G/C Genotypic n(dd/dD/DD)  91/323/288 35/113/107 0,888 1 20/85/59 13/53/34 0,935 1 47/172/123 34/128/106 0,659 1 
   
Allelic n(d/D) 505/899 183/327 1,000 1 125/203 79/121 0,783 1 266/418 196/340 0,440 1 
   
Dominant n(dd+dD/DD) 414/288 148/107 0,824 1 105/59 66/34 0,791 1 219/123 162/106 0,400 1 
rs905721 162335052 T/C Genotypic n(dd/dD/DD)  94/322/282 38/116/104 0,868 1 18/80/59 13/51/33 0,811 1 49/171/122 33/130/105 0,605 1 
   
Allelic n(d/D) 510/886 192/324 0,790 1 116/198 77/117 0,573 1 269/415 196/340 0,342 1 
   
Dominant n(dd+dD/DD) 416/282 154/104 1,000 1 98/59 64/33 0,593 1 220/122 163/105 0,399 1 
rs348624 162335256 T/C Genotypic n(dd/dD/DD)  10/141/537 3/51/194 1,000 1 2/23/135 1/19/76 0,584 1 -- -- -- -- 
   
Allelic n(d/D) 161/1215 57/439 0,935 1 27/293 21/171 0,352 1 -- -- -- -- 
   
Dominant n(dd+dD/DD) 151/537 54/194 1,000 1 25/135 20/76 0,312 1 -- -- -- -- 
rs1964052 162335424 T/C Genotypic n(dd/dD/DD)  10/145/545 3/55/195 0,948 1 2/25/136 1/19/79 0,777 1 2/70/268 5/53/203 0,394 1 
   
Allelic n(d/D) 165/1235 61/445 0,873 1 29/297 21/177 0,542 1 74/606 63/459 0,523 1 
   
Dominant n(dd+dD/DD) 155/545 58/195 0,792 1 27/136 20/79 0,508 1 72/268 58/203 0,765 1 
SYN2; Chromosome 3: 
rs598747 12112010 C/T Genotypic n(dd/dD/DD)  9/152/537 6/57/190 0,439 1 4/51/106 3/28/69 0,761 1 -- -- -- -- 
   
Allelic n(d/D) 170/1226 69/437 0,390 1 59/263 34/166 0,726 1 -- -- -- -- 
   
Dominant n(dd+dD/DD) 161/537 63/190 0,546 1 55/106 31/69 0,685 1 -- -- -- -- 
rs598704 12112053 C/T Genotypic n(dd/dD/DD)  40/254/403 16/101/129 0,329 1 17/67/73 5/42/50 0,291 1 21/139/185 17/108/142 1,000 1 
   
Allelic n(d/D) 334/1060 133/359 0,182 1 101/213 52/142 0,232 1 181/509 142/392 0,896 1 
   
Dominant n(dd+dD/DD) 294/403 117/129 0,156 1 84/73 47/50 0,442 1 160/185 125/142 0,935 1 
rs308969 12177083 C/T Genotypic n(dd/dD/DD)  10/107/584 0/47/208 0,080 1 2/34/128 2/19/78 0,824 1 3/70/269 0/40/228 0,049 1 
   
Allelic n(d/D) 127/1275 47/463 0,928 1 38/290 23/175 1,000 1 76/608 40/496 0,039 1 
   
Dominant n(dd+dD/DD) 117/584 47/208 0,561 1 36/128 21/78 1,000 1 73/269 40/228 0,046 1 
rs3817004 12195674 G/A Genotypic n(dd/dD/DD)  0/42/656 2/17/236 0,098 1 0/16/148 0/8/92 0,826 1 1/23/316 1/22/245 0,770 1 
   
Allelic n(d/D) 42/1354 21/489 0,247 1 16/312 8/192 0,830 1 25/655 24/512 0,557 1 
   
Dominant n(dd+dD/DD) 42/656 19/236 0,455 1 16/148 8/92 0,826 1 24/316 23/245 0,542 1 
ss35528972 12197255 T/A Genotypic n(dd/dD/DD)  3/73/618 0/30/227 0,636 1 1/21/135 0/9/88 0,644 1 2/48/294 0/30/237 0,364 1 
   
Allelic n(d/D) 79/1309 30/484 0,912 1 23/291 9/185 0,263 1 52/636 30/504 0,205 1 
   
Dominant n(dd+dD/DD) 76/618 30/227 0,729 1 22/135 9/88 0,326 1 50/294 30/237 0,277 1 
rs3755724 12200906 T/C Genotypic n(dd/dD/DD)  71/294/327 26/103/120 0,959 1 19/84/54 11/51/36 0,932 1 29/149/149 33/102/127 0,158 1 
   
Allelic n(d/D) 436/948 155/343 0,910 1 122/192 73/123 0,779 1 207/447 168/356 0,900 1 
   
Dominant n(dd+dD/DD) 365/327 129/120 0,825 1 103/54 62/36 0,788 1 178/149 135/127 0,507 1 
NOS1; Chromosome 12: 
rs3782206 117745089 T/C Genotypic n(dd/dD/DD)  7/141/548 1/52/206 0,835 1 2/30/126 4/17/76 0,347 1 2/72/268 2/66/199 0,530 1 
   
Allelic n(d/D) 155/1237 54/464 0,681 1 34/282 25/169 0,478 1 76/608 70/464 0,288 1 
   
Dominant n(dd+dD/DD) 148/548 53/206 0,858 1 32/126 21/76 0,874 1 74/268 68/199 0,289 1 
rs499776 117779499 A/G Genotypic n(dd/dD/DD)  123/331/243 32/145/82 0,038 1 12/90/55 20/37/40 0,002 0,046 58/166/119 34/121/113 0,117 1 
   
Allelic n(d/D) 577/817 209/309 0,714 1 114/200 77/117 0,452 1 282/404 189/347 0,038 0,997 
   
Dominant n(dd+dD/DD) 454/243 177/82 0,398 1 102/55 57/40 0,351 1 224/119 155/113 0,065 1 
rs3782219 117788240 T/C -- -- -- -- -- 4/55/100 6/23/68 0,080 1 -- -- -- -- 
   
-- -- -- -- -- 63/255 35/159 0,645 1 -- -- -- -- 
   
-- -- -- -- -- 59/100 29/68 0,278 1 -- -- -- -- 
rs3782221 117795881 A/G Genotypic n(dd/dD/DD)  31/244/420 13/93/146 0,740 1 5/62/92 7/26/67 0,052 1 17/127/196 23/95/144 0,184 1 
   
Allelic n(d/D) 306/1084 119/385 0,455 1 72/246 40/160 0,512 1 161/519 141/383 0,203 1 
   
Dominant n(dd+dD/DD) 275/420 106/146 0,500 1 67/92 33/67 0,151 1 144/196 118/144 0,562 1 
rs1879417 117803515 T/C Genotypic n(dd/dD/DD)  163/349/178 65/130/57 0,561 1 26/91/45 28/43/28 0,044 1 72/169/97 51/132/84 0,702 1 
   
Allelic n(d/D) 675/705 260/244 0,323 1 143/181 99/99 0,206 1 313/363 234/300 0,416 1 
   
Dominant n(dd+dD/DD) 512/178 195/57 0,350 1 117/45 71/28 1,000 1 241/97 183/84 0,475 1 
rs4767540 117877007 G/A Genotypic n(dd/dD/DD)  160/324/213 64/122/71 0,638 1 28/76/51 17/42/36 0,688 1 67/160/118 47/129/89 0,817 1 
   
Allelic n(d/D) 644/750 250/264 0,352 1 132/178 76/114 0,577 1 294/396 223/307 0,861 1 
   
Dominant n(dd+dD/DD) 484/213 186/71 0,425 1 104/51 59/36 0,494 1 227/118 176/89 0,931 1 
rs41279104 117877485 T/C Genotypic n(dd/dD/DD)  8/130/559 2/66/184 0,035 0,979 3/35/124 2/24/72 0,877 1 9/64/268 4/55/209 0,567 1 
   
Allelic n(d/D) 146/1248 70/434 0,041 1 41/283 28/168 0,596 1 82/600 63/473 0,929 1 
   
Dominant n(dd+dD/DD) 138/559 68/184 0,020 0,571 38/124 26/72 0,656 1 73/268 59/209 0,921 1 
DYNLL1 (PIN); Chromosome 12: 
rs12857 120933946 T/G Genotypic n(dd/dD/DD)  21/202/471 11/64/174 0,374 1 7/47/103 4/34/59 0,679 1 17/101/186 11/76/170 0,452 1 
   
Allelic n(d/D) 244/1144 86/412 0,945 1 61/253 42/152 0,571 1 135/473 98/416 0,210 1 
   
Dominant n(dd+dD/DD) 223/471 75/174 0,579 1 54/103 38/59 0,502 1 118/186 87/170 0,253 1 
rs787828 120937086 T/A Genotypic n(dd/dD/DD)  86/296/320 27/128/99 0,081 1 20/70/70 10/41/48 0,722 1 51/155/136 47/121/100 0,644 1 
   
Allelic n(d/D) 468/936 182/326 0,325 1 110/210 61/137 0,442 1 257/427 215/321 0,375 1 
   
Dominant n(dd+dD/DD) 382/320 155/99 0,077 1 90/70 51/48 0,521 1 206/136 168/100 0,558 1 
rs9788155 120938408 A/G Genotypic n(dd/dD/DD)  68/292/338 23/105/131 0,845 1 16/65/76 12/38/46 0,867 1 22/123/197 26/101/141 0,242 1 
   
Allelic n(d/D) 428/968 151/367 0,538 1 97/217 62/130 0,768 1 167/517 153/383 0,116 1 
   
Dominant n(dd+dD/DD) 360/338 128/131 0,561 1 81/76 50/46 1,000 1 145/197 127/141 0,220 1 
RASD1 (DEXRAS1); Chromosome 17: 
rs4924755 17397131 G/C Genotypic n(dd/dD/DD)  60/280/363 16/100/137 0,515 1 7/48/108 1/33/65 0,340 1 33/133/175 31/110/127 0,561 1 
   
Allelic n(d/D) 400/1006 132/374 0,326 1 62/264 35/163 0,729 1 199/483 172/364 0,287 1 
   
Dominant n(dd+dD/DD) 340/363 116/137 0,510 1 55/108 34/65 1,000 1 166/175 141/127 0,369 1 
rs711352 17397818 C/G Genotypic n(dd/dD/DD)  56/261/378 13/92/144 0,300 1 7/43/108 1/30/67 0,319 1 24/124/189 25/107/136 0,351 1 
   
Allelic n(d/D) 373/1017 118/380 0,190 1 57/259 32/164 0,719 1 172/502 157/379 0,153 1 
      Dominant n(dd+dD/DD) 317/378 105/144 0,373 1 50/108 31/67 1,000 1 148/189 132/136 0,218 1 
Table 2:  Association results for haplotypes examined in the German, Swedish and Spanish samples along with frequencies in cases and controls, nominal P-
values of χ2-Tests in one degree of freedom and the Bonferroni-corrected p-values, corrected over all haplotypes. Bold indicates significant haplotypes p<0.05 in 
at least one sample. 
      
German sample Swedish sample Spanish sample 
NOS1AP (Capon); Chromosome 1 Frequencies Nominal Bonferroni Frequencies Nominal Bonferroni Frequencies Nominal Bonferroni 
Block1: rs1415263 rs4306106 rs3924139     Case/Control P-Value P-Value Case/Control P-Value P-Value Case/Control P-Value P-Value 
 
T A G 
  
0,24/0,21 0,206 1 0,22/0,31 0,018 0,527 0,28/0,29 0,796 1 
 
T G G 
  
0,15/0,14 0,500 1 0,11/0,14 0,361 1 0,13/0,11 0,427 1 
 
C G G 
  
0,02/0,02 0,822 1 0,01/0,02 0,182 1 -- -- -- 
 
T G A 
  
0,06/0,06 0,901 1 0,05/0,05 0,963 1 0,04/0,05 0,467 1 
  C G A     0,56/0,60 0,130 1 0,64/0,50 0,002 0,066 0,55/0,55 0,984 1 
  Frequencies Nominal Bonferroni Frequencies Nominal Bonferroni Frequencies Nominal Bonferroni 
Block2: rs7521206 rs905721 rs348624 rs1964052   Case/Control P-Value P-Value Case/Control P-Value P-Value Case/Control P-Value P-Value 
 
C C T T 
 
0,12/0,12 0,944 1 0,11/0,09 0,575 1 0,12/0,11 0,546 1 
 
G T C C 
 
0,37/0,37 0,848 1 0,40/0,38 0,765 1 0,36/0,39 0,334 1 
  C C C C   0,52/0,53 0,889 1 0,51/0,54 0,537 1 0,52/0,5 0,577 1 
SYN2; Chromosome 3: 
   
Frequencies Nominal Bonferroni Frequencies Nominal Bonferroni Frequencies Nominal Bonferroni 
Block1: rs598747 rs598704 rs308969 rs3817004 ss35528972 Case/Control P-Value P-Value Case/Control P-Value P-Value Case/Control P-Value P-Value 
 
C C C A T 0,06/0,06 0,937 1 0,05/0,07 0,268 1 0,06/0,08 0,169 1 
 
C C T G A 0,04/0,04 0,358 1 0,05/0,05 0,739 1 0,04/0,04 0,564 1 
 
C C C A A 0,04/0,04 0,795 1 0,07/0,05 0,325 1 0,02/0,03 0,111 1 
 
C C T A A -- -- -- 0,02/0,02 0,729 1 0,15/0,12 0,118 1 
 
T C T A A 0,13/0,12 0,534 1 0,10/0,14 0,144 1 -- -- -- 
  T T T A A 0,74/0,77 0,314 1 0,74/0,68 0,174 1 0,73/0,74 0,936 1 
NOS1; Chromosome 12: Frequencies Nominal Bonferroni Frequencies Nominal Bonferroni Frequencies Nominal Bonferroni 
Block1: rs3782206 rs499776       Case/Control P-Value P-Value Case/Control P-Value P-Value Case/Control P-Value P-Value 
 
C A 
   
0,41/0,42 0,725 1 0,40/0,37 0,444 1 0,34/0,04 0,032 0,895 
 
T G 
   
0,11/0,11 0,807 1 0,13/0,11 0,482 1 0,12/0,10 0,260 1 
  C G       0,50/0,49 0,621 1 0,48/0,53 0,233 1 0,53/0,49 0,166 1 
  Frequencies Nominal Bonferroni Frequencies Nominal Bonferroni Frequencies Nominal Bonferroni 
Block2: rs3782219 rs3782221 rs1879417     Case/Control P-Value P-Value Case/Control P-Value P-Value Case/Control P-Value P-Value 
 
C G C 
  
-- -- -- 0,51/0,45 0,188 1 0,42/0,44 0,339 1 
 
T A T 
  
-- -- -- 0,20/0,22 0,507 1 0,24/0,22 0,284 1 
 
C G T 
  
-- -- -- 0,31/0,34 0,409 1 0,32/0,32 0,954 1 
  Frequencies Nominal Bonferroni Frequencies Nominal Bonferroni Frequencies Nominal Bonferroni 
Block3: rs4767540 rs41279104       Case/Control P-Value P-Value Case/Control P-Value P-Value Case/Control P-Value P-Value 
 
G T 
   
0,15/0,11 0,028 0,722 0,16/0,13 0,469 1 0,12/0,12 0,955 1 
 
G C 
   
0,35/0,36 0,565 1 0,26/0,30 0,285 1 0,3/0,31 0,825 1 
  A C       0,52/0,55 0,394 1 0,6/0,58 0,637 1 0,58/0,57 0,865 1 
DYNLL1 (PIN); Chromosome 12: Frequencies Nominal Bonferroni Frequencies Nominal Bonferroni Frequencies Nominal Bonferroni 
Block1: rs12857 rs787828 rs9788155     Case/Control P-Value P-Value Case/Control P-Value P-Value Case/Control P-Value P-Value 
 
G A A 
  
0,29/0,31 0,520 1 0,33/0,31 0,684 1 0,28/0,24 0,118 1 
 
G T G 
  
0,36/0,34 0,279 1 0,31/0,35 0,363 1 0,4/0,38 0,363 1 
 
T A G 
  
0,18/0,18 0,859 1 0,21/0,20 0,680 1 0,18/0,22 0,102 1 
 
G A G 
  
0,18/0,19 0,698 1 0,16/0,16 0,837 1 0,13/0,16 0,183 1 
RASD1 (DEXRAS1); Chromosome 17: Frequencies Nominal Bonferroni Frequencies Nominal Bonferroni Frequencies Nominal Bonferroni 
Block1: rs4924755 rs711352       Case/Control P-Value P-Value Case/Control P-Value P-Value Case/Control P-Value P-Value 
 
G C 
   
0,24/0,27 0,171 1 0,17/0,19 0,640 1 0,29/0,25 0,140 1 
 
G G 
   
0,03/0,02 0,685 1 -- -- -- 0,03/0,04 0,305 1 
  C G       0,75/0,72 0,222 1 0,84/0,82 0,640 1 0,68/0,71 0,306 1 
 
Table 3: Meta-analysis of 12 NOS1AP variants. Table shows all SNPs along with their minor/major alleles, cases and control counts for the genotypic and 
dominant model as well as the nominal p-values for each sample and the total sample. Further are given p-values for heterogeneity and odds ratios plus p-values 
of the fixed effect and random effect model. Bold indicates SNPs with at least one significant p-value (p<0.05). 
SNPs rs1572495 rs1538018 rs945713 rs1415263 rs4306106 rs3924139 rs1508263 rs3751284 rs7521206 rs905721 rs348624 rs1964052 
Alleles 
(d/D) 
T/C C/G C/T T/C A/G G/A A/G A/G G/C T/C T/C T/C 
Test d/D d+/d- d/D d+/d- d/D d+/d- d/D d+/d- d/D d+/d- d/D d+/d- d/D d+/d- d/D d+/d- d/D d+/d- d/D d+/d- d/D d+/d- d/D d+/d- 
German sample (Controls: n=720; Cases: n=270) 
Controls 122/1282 115/587 -- -- 543/853 441/257 547/857 440/262 289/1101 253/442 493/901 409/288 636/756 497/199 487/903 397/298 505/899 414/288 510/886 416/282 161/1215 151/537 165/1235 155/545 
Cases 45/465 42/213 -- -- 244/276 187/73 220/290 177/78 121/395 107/151 202/316 162/97 211/279 165/80 174/336 145/110 183/327 148/107 192/324 154/104 57/439 54/194 61/445 58/195 
P-value 0,927 1,000 -- -- 0,002* 0,012 0,102 0,056 0,210 0,154 0,149 0,299 0,317 0,255 0,744 0,941 1,000 0,824 0,790 1,000 0,935 1,000 0,873 0,792 
Swedish sample (Controls: n=168; Cases: n=101) 
Controls 24/302 23/140 73/237 65/90 143/169 107/49 155/167 117/44 96/214 80/75 145/169 112/45 136/170 102/51 125/199 95/67 125/203 105/59 116/198 98/59 27/293 25/135 29/297 27/136 
Cases 11/189 11/89 51/143 43/54 72/122 60/37 71/127 61/38 41/153 38/59 63/131 56/41 99/91 74/21 70/130 62/38 79/121 66/34 77/117 64/33 21/171 20/76 21/177 20/79 
P-value 0,474 0,571 0,524 0,794 0,064 0,278 0,006 0,074 0,018 0,069 0,003 0,029 0,116 0,063 0,457 0,606 0,783 0,791 0,573 0,593 0,352 0,312 0,542 0,508 
Spanish sample (Controls: n=360; Cases: n=270) 
Controls 60/624 58/284 -- -- 288/398 225/118 304/378 233/108 197/489 168/175 284/406 219/126 314/370 245/97 232/440 200/136 266/418 219/123 269/415 220/122 -- -- 74/606 72/268 
Cases 49/487 45/223 -- -- 237/297 188/79 238/292 188/77 150/382 134/132 221/313 180/87 202/330 172/94 177/357 144/123 196/340 162/106 196/340 163/105 -- -- 63/459 58/203 
P-value 0,840 1,000 -- -- 0,415 0,222 0,954 0,534 0,848 0,744 0,953 0,347 0,006 0,078 0,625 0,185 0,440 0,400 0,342 0,399 -- -- 0,523 0,765 
Nicodemus et al., 2010 (Controls: n=487; Cases: n=415) 
                 
Controls 94/646 81/288 140/476 126/182 296/422 243/116 309/429 248/121 -- -- -- -- -- -- 263/469 214/152 -- -- -- -- 106/516 92/219 -- -- 
Cases 55/585 53/267 152/392 132/140 238/394 193/123 242/388 201/114 -- -- -- -- -- -- 234/400 202/115 -- -- -- -- 67/485 62/214 -- -- 
P-value 0,014 0.075 0,041 0.065 0,181 0,073 0,194 0,351 -- -- -- -- -- -- 0,707 0,161 -- -- -- -- 0,018 0,050 -- -- 
Delorme et al., 2010 (Controls: n=286; Cases: n=296) 
Controls -- -- -- -- -- -- -- -- -- -- -- -- -- -- 61/91 50/26 -- -- 189/309 147/102 34/283 31/128 34/283 31/128 
Cases -- -- -- -- -- -- -- -- -- -- -- -- -- -- 30/58 24/20 -- -- 213/353 169/114 74/500 69/218 74/500 69/218 
P-value -- -- -- -- -- -- -- -- -- -- -- -- -- -- 0,353 0,222 -- -- 0,914 0,873 0,343 0,270 0,343 0,270 
Puri et al., 2005 (Controls: n=450; Cases: n=450) 
Controls 81/797 -- 207/631 -- 321/539 -- 331/549 -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- 
Cases 65/715 -- 182/598 -- 294/486 -- 270/502 -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- 
P-value 0,522 -- 0,520 -- 0,878 -- 0,266 -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- 
Zheng et al., 2005 (Controls: n=941; Cases: n=664) 
Controls 359/1523 324/617 -- -- 1354/528 868/73 882/1000 660/274 -- -- -- -- -- -- 1115/767 776/165 -- -- 961/921 716/225 346/1536 319/622 -- -- 
Cases 253/1075 228/436 -- -- 959/369 609/55 660/668 489/175 -- -- -- -- -- -- 784/544 544/120 -- -- 700/628 521/143 169/1159 155/509 -- -- 
P-value 0,990 0,969 -- -- 0,870 0,702 0,114 0,191 -- -- -- -- -- -- 0,905 0,781 -- -- 0,357 0,265 2*10-5 5*10-6 -- -- 
Total (Controls: n=3412; Cases: n=2406) 
                    
Controls 740/5174 601/1916 420/1344 191/272 2945/2909 1884/613 2528/3380 1698/809 582/1804 501/692 922/1476 740/459 1086/1296 844/347 2283/2869 1732/844 896/1520 738/470 2045/2729 1597/790 674/3843 618/1641 302/2421 285/1077 
Cases 478/3516 379/1228 385/1133 175/194 2044/1944 1237/367 1701/2267 1116/482 312/930 279/342 486/760 398/225 512/700 411/195 1469/1825 1121/526 458/788 376/247 1378/1762 1071/499 388/2754 360/1211 219/1581 205/695 
Heterogeneity:  
P-value 0.301 -- 0.138 -- 0.008 -- 0.008 -- 0.026 0.06 0.003 0.033 0.015 0.035 0.891 0.340 0.732 0.731 0.270 0.712 0.009 0.004 0.906 0.854 
Cochran-Mantel-Haenszel Metaanalysis: 
Fixed 
effect 0,91 -- 1,09 -- 1,04 -- 1,00 -- 0,98 1,04 0,99 1,06 0.88 0.87 0,97 0,99 0,97 0,94 1,09 1,04 0,78 0,77 1,12 1,12 
P-value 0.142 -- 0.316 -- 0.426 -- 0.983 -- 0.819 0.706 0.911 0,877 0.086 0.237 0.541 0.858 0.710 0.579 0.064 0.633 0.0004 0.001 0.295 0.307 
DerSimonian and Laird  Metaanalysis: 
Random 
effect 0,90 -- 1,11 -- 1,23 -- 1,04 -- 0,92 0.98 0.90 0,97 0,93 0.95 0,97 0,98 0,97 0,94 1,10 1,04 0,88 0,89 1,11 1,12 
P-value 0.144 -- 0.397 -- 0.836 -- 0.596 -- 0.599 0.903 0,565 0,877 0.648 0.812 0.527 0.830 0.684 0.543 0.098 0.611 0.366 0,502 0.275 0.285 
 *significant after Bonferroni correction (p<0.05) 
  
Table 4: Meta-analysis of 7 NOS1 variants. Table shows all SNPs along with their minor/major alleles, cases and control counts for the genotypic and dominant 
model as well as the nominal p-values for each sample and the total sample. Further are given p-values for heterogeneity and odds ratios plus p-values of the 
fixed effect and random effect model. Bold indicates SNPs with at least one significant p-value (p<0.05). 
 
SNPs rs3782206 rs499776 rs3782219 rs3782221 rs1879417 rs4767540 rs41279104 
Alleles (d/D) T/C A/G T/C A/G T/C G/A T/C 
Test d/D d+/d- d/D d+/d- d/D d+/d- d/D d+/d- d/D d+/d- d/D d+/d- d/D d+/d- 
German sample (Controls: n=720; Cases: n=270) 
Controls 155/1237 148/548 577/817 454/243 -- -- 306/1084 275/420 675/705 512/178 644/750 484/213 146/1248 138/559 
Cases 54/464 53/206 209/309 177/82 -- -- 119/385 106/146 260/244 195/57 250/264 186/71 70/434 68/184 
P-value 0,681 0,858 0,714 0,398 -- -- 0,455 0,500 0,323 0,350 0,352 0,425 0,041 0,020 
Swedish sample (Controls: n=168; Cases: n=101) 
Controls 34/282 32/126 114/200 102/55 63/255 59/100 72/246 67/92 143/181 117/45 132/178 104/51 41/283 38/124 
Cases 25/169 21/76 77/117 57/40 35/159 29/68 40/160 33/67 99/99 71/28 76/114 59/36 28/168 26/72 
P-value 0,478 0,874 0,452 0,351 0,645 0,278 0,512 0,151 0,206 1,000 0,577 0,494 0,596 0,656 
Spanish sample (Controls: n=360; Cases: n=270) 
Controls 76/608 74/268 282/404 224/119 -- -- 161/519 144/196 313/363 241/97 294/396 227/118 82/600 73/268 
Cases 70/464 68/199 189/347 155/113 -- -- 141/383 118/144 234/300 183/84 223/307 176/89 63/473 59/209 
P-value 0,288 0,289 0,038 0,065 -- -- 0,203 0,562 0,416 0,475 0,861 0,931 0,929 0,921 
Cui et al., 2010 (Controls: n=377; Cases: n=343) 
Controls 197/557 164/213 -- -- 302/448 247/128 347/403 270/105 -- -- -- -- 132/622 119/258 
Cases 161/525 146/197 -- -- 289/397 236/107 303/383 232/111 -- -- -- -- 168/518 147/196 
P-value 0,244 0,800 -- -- 0,474 0,402 0,425 0,203 -- -- -- -- 0,001 0,002 
Okumura et al., 2009 (Controls: n=519; Cases: n=542) 
Controls 641/1879 554/706 -- -- 1121/1399 866/394 441/597 344/175 -- -- -- -- 182/856 165/354 
Cases 645/1663 544/610 -- -- 950/1358 745/409 486/598 369/173 -- -- -- -- 212/872 187/355 
P-value 0,049 0,118 -- -- 0,020 0,030 0,276 0,532 -- -- -- -- 0,231 0,349 
Tang et al., 2008 (Controls: n=480; Cases: n=480) 
Controls 218/718 186/282 204/742 185/288 404/540 315/157 458/428 332/111 498/430 366/98 185/751 168/300 -- -- 
Cases 266/676 221/250 162/784 152/321 409/525 319/148 493/407 355/85 497/449 365/108 188/740 168/296 -- -- 
P-value 0,014 0,026 0,015 0,025 0,664 0,607 0,191 0,040 0,625 0,527 0,790 0,922 -- -- 
Total (Controls: n=2624; Cases: n=2006) 
          
Controls 1321/5281 1158/2143 1177/2163 965/705 1890/2642 1487/779 1785/3277 1432/1099 1629/1679 1236/418 1255/2075 983/682 583/3609 533/1563 
Cases 1221/3961 1053/1538 637/1557 541/556 1683/2439 1329/732 1582/2316 1213/726 1090/1092 814/277 737/1425 589/492 541/2465 487/1016 
Heterogeneity:  
P-value 0.166 0.557 0.139 0.114 0.209 0.151 0.524 0.128 0.299 0.597 0.764 0.722 0.245 0.256 
Cochran-Mantel-Haenszel Metaanalysis: 
Fixed effect 1,11 1,13 0,86 0.84 0.94 0.92 1,07 1,07 1,01 0.98 1,03 1,03 1,25 1,29 
P-value 0.024 0.030 0.020 0.039 0.182 0.195 0.161 0.425 0.826 0.849 0.700 0.754 0.001 0.001 
DerSimonian and Laird  Metaanalysis: 
Random effect 1,10 1,13 0,87 0.84 0.96 0.94 1,07 1,07 1,02 0.98 1,03 1,03 1,25 1,29 
P-value 0.152 0.028 0.112 0.147 0.524 0.542 0.157 0.153 0.781 0.802 0.677 0.727 0.006 0.005 
 
  
 
Supplementary Figure 1: Funnel plots of NOS1AP rs3782206 dominant and allelic model (A), NOS1 rs499776 dominant and allelic model (B) and NOS1 rs41279104 
dominant and allelic model (C). 
Supplementary Table 1: Primer sequences in 5’-3’ direction used for Sequenom’s MassArray® system.  
SNP ID Primary PCR Primer 1 Primary PCR Primer 2 Extend Primer 
rs12857 ACGTTGGATGCTTAGATGCGCCACGGTTTC ACGTTGGATGGGTGCTAGCACAGCTCAGG tTTTCGGTAGCGACGGTA 
rs3916065 ACGTTGGATGAAAGCGCCACCTAGCAACG ACGTTGGATGCAGGAACCACACAGAAGGG ggaacCGGTATCTAAGATCAGGGAGC 
rs787828 ACGTTGGATGGCAGTCACCTAGCTGCTTAG ACGTTGGATGGGTCCTGACTTGTAGTTAGC tttccCCTAGCTGCTTAGAAATCCC 
rs1415263 ACGTTGGATGCTAAATGGTGAGCCCCAATG ACGTTGGATGTGGGTTGGAAGGCAACATAC accTTAGGCATTCCCAATTCCTTTATC 
rs4145621 ACGTTGGATGCCATCACCCCTTGATAAAAG ACGTTGGATGGACTTAAATCCAACTCTTC TGCTGTGGTTTGATGGAGAA 
rs348624 ACGTTGGATGCCTTGTTCTGCAGCAAAAGC ACGTTGGATGACCAGTTGGCTGCTGAGG gctgaAGCAAAAGCTGATGCAC 
rs9788155 ACGTTGGATGGACAGATCATCCGTTCTGAG ACGTTGGATGTGAAGCCCACAGGGAATTTG GTTCTGAGTAGGGCTTAA 
rs1572495 ACGTTGGATGCTTCAGAGGATGCAGATTTG ACGTTGGATGCCCTGCCTAAATATCCTTTG ATGCAGATTTGAGCTGAGCC 
rs1538018 ACGTTGGATGCCAACTCTGAACTTAGGATG ACGTTGGATGACTTTCTCCCTAAGTGGCCC GGATGAAAAGGAGAACAATGA 
rs945713 ACGTTGGATGCTGTGTGACACTCCCATTTG ACGTTGGATGGATAACTTCAGTTTTTTGAC TCCCATTTGGATATCCCAAAG 
rs3751284 ACGTTGGATGTGCAGATGGCCAGGAAGATG ACGTTGGATGACAGAAGCCGCAGTGCCTAC CAGGAAGATGGAGAGAG 
rs905721 ACGTTGGATGCCTCCTCTGGAATGATAAGC ACGTTGGATGATGCCCTCCACATTCAGTTC ccTGATAAGCCCAGATGCC 
rs1964052 ACGTTGGATGCTGGAATATAGGGGTAGGTC ACGTTGGATGAAGGCTCTGGAAAGAGTGTC cAGAAAGCACCACCAAAAACTTA 
rs4306106 ACGTTGGATGTATCGCTTTCAGGGTCAAGG ACGTTGGATGGAAGAAGAAGAATGAATTTC ctcacAAAACTCAGTAAAGCTACCC 
rs3924139 ACGTTGGATGCAGTGTTGTATACAATGCGG ACGTTGGATGAACAACTGCCTGTGCTCAAG aaAATGCGGTATATAATATCTAACA 
rs1508263 ACGTTGGATGGGGACAGCCGTTTAGTTAC ACGTTGGATGTGATCTCACTATTAAGTTG agggcGTTACTTGGTAGTGAAAGAAA 
rs7521206 ACGTTGGATGGCCGTAGTGTCACATCACTC ACGTTGGATGCTGTGTTGTCTTTGGCAATG cacgCTGTGCCACATCACTGA 
rs4924755 ACGTTGGATGCAGAGAGATTGGTGTTCTGG ACGTTGGATGTGTAGAGCCCCATCCCCCTT ttTGCCTTAGCCATGAGAC 
rs711352 ACGTTGGATGGACACGAACAAAACCTTACC ACGTTGGATGAAACCAAATAAAGCAATAAC cccctGTGTTTATACTGTGTGTGT 
rs2232841 ACGTTGGATGGTTAAGTCAAATCCAACGGC ACGTTGGATGGATCGCCGGGAGGGGAGAC AATCCAACGGCCCGGTGCGCCCC 
rs2232838 ACGTTGGATGGCCAAAGGCAGAGCAAGCG ACGTTGGATGCTCGGGCTAGGCTGGGCT gttTGCCCAGATCCTGGGAG 
rs4767540 ACGTTGGATGGCTTTAGGGTTTCCACTCTG ACGTTGGATGAGGCTTAGAGTCCCAGACAG TTCCACTCTGCCCTCAT 
rs1879417 ACGTTGGATGCTCTACTCGGCCTTCAAGTC ACGTTGGATGGAAGAGGGACATGCAGAGTG GCCTTCAAGTCTTAGCG 
rs3782221 ACGTTGGATGCTTAACCACATTCCAAGCCC ACGTTGGATGGGGTGTCTTATGACAAGACT ccaCGCACAGACCCACAGAACCTGAGT 
rs3782219 ACGTTGGATGTCCAGGGCATTGCAACTTAG ACGTTGGATGCACCTCCTCAATTAACTGGG tgcacCTTAGCCTGCAAATTGTAG 
rs499776 ACGTTGGATGCTACATACCTGCCCCATTGC ACGTTGGATGCAAACCCTGGTTTTTCTAGC GCCCCATTGCTGTAAAT 
rs3837437 ACGTTGGATGTGAAGAATGTTGTTAGGTGC ACGTTGGATGCTGGGTGACAGAGCAAGAAC ggaAATGTTGTTAGGTGCTTTTTTT 
rs3782206 ACGTTGGATGCTACACACACAAAAGTCTTTC ACGTTGGATGAGTAAGGAAGGCTGGGTAAC ccctgTAAATATGCAACTAAATGTCCT 
rs598747 ACGTTGGATGCATGAAGAAGATTTGGCACC ACGTTGGATGTCAGCAGCACCAGGTGCTC cttGCACCACACCTTCTACA 
rs598704 ACGTTGGATGTGAGTTGCGTGTGGCCCCG ACGTTGGATGTCTTCTCTCTGTTGGCCTTG AGGAGCACCTGGTGCTGCTGAC 
rs308969 ACGTTGGATGGCTAATGGACCTGAAAGAGC ACGTTGGATGCTAGCCTGAGATTTGATCCT ccCCTAGAGTATAAATCCTCCCA 
rs931676 ACGTTGGATGCACTTTCCACCCATGGCTTG ACGTTGGATGTTGCAGTATGCAGGCCTCC GGCTTGTCACAGAAGTT 
rs3817004 ACGTTGGATGTCCCAGCCAAAGTGTAAGTA ACGTTGGATGCTGCACTGTATGAAGTTGGG CAGCCAAAGTGTAAGTACTTTGAG 
rs35528972 ACGTTGGATGTGCTAGGCATGGAGGTACAG ACGTTGGATGCACCCTCAGTTAGACTTGAC ctaatGGGAAATGAGGAAACATG 
rs3755724 ACGTTGGATGTTGGAGCCTCATAAATAGGG ACGTTGGATGGAATGAGACGAGCTACTCAG cccagCTCATAAATAGGGCATTGAAA 
rs41279104 ACGTTGGATGAAGGCTTGGCCTCCCAACC ACGTTGGATGTTTAATTGACACCAGGTGGC cccCCTCCCAACCCAGCAGAGCC 
 
 
  
Supplementary Table 2: Functional prediction of rs945713, rs3782206, rs499776 and rs41279104 (in bold and highlighted grey) and their proxy SNPs in 
high linkage disequilibrium (r
2 
≥ 0.8 and D´=1). All Transcription Factors (TFs), shown in table have a core similarity of 1 and a matrix similarity of 0.85 and more. 
Changes in Splicing Regulatory Elements (SREs), like Splicing Enhancers (Srp40, SF2/ASF, SC35, SRp55, 9G8, Tra-ß) and Splicing Inhibitors (hnRNP A1) with 
a match similarity of at least 65.0  are shown for minor and major alleles. 
 
Associated 
SNP 
Proxy SNP Position 
(bp) 
Alleles 
(d/D) 
location Transcription Factor (TF) 
Minor Allele (d) Major Allele (D) 
NOS1AP; chromosome 1 
rs945713 rs10918796 162133343 C/A Intron SF2/ASF 9G8,hnRNP A1 
rs945713 rs10918797 162133602 A/G Intron 9G8 SF2/ASF 
rs945713 rs6427656 162134638 G/A Intron - - 
rs945713 rs945713 162135670 G/A Intron hnRNP A1 9G8,Tra2-β 
rs945713 rs11581189 162136904 C/T Intron SRp55 SC35 
rs945713 rs11805598 162140336 A/G Intron 9G8,Tra2-β,hnRNP 
A1 
- 
rs945713 rs7549718 162140862 A/G Intron Tra2-β,9G8 - 
NOS1; chromosome 12 
rs3782206 rs7961147 117738879 T/C Intron Tra2-β   
rs3782206 rs12578810 117738948 T/C Intron Tra2-β SF2/ASF, 9G8, hnRNP 
A1 
rs3782206 rs12810591 117739450 C/T Intron - SRp40,hnRNP A1 
rs3782206 rs12811583 117739942 C/T Intron - SRp55 
rs3782206 rs3825103 117740509 C/T Intron - 9G8, hnRNP A1 
rs3782206 rs12811676 117741229 A/G Intron - SRp40, SC35, SF2/ASF 
rs3782206 rs12812274 117742714 A/G Intron - - 
rs3782206 rs6490124 117743269 C/A Intron 9G8 - 
rs3782206 rs7139134 117743766 T/C Intron Tra2-β hnRNP A1 
rs3782206 rs11068444 117744743 G/A Intron SRp55 hnRNP A1 
rs3782206 rs11068445 117744929 A/G Intron hnRNP A1 SRp40 
rs3782206 rs3782206 117745089 T/C Intron - - 
rs3782206 rs35555584 117746177 C/A Intron SF2/ASF SC35, hnRNP A1 
rs3782206 rs7310618 117747306 G/C Intron SRp55 - 
rs3782206 rs7299154 117747395 G/T Intron - SF2/ASF 
rs3782206 rs10850809 117747441 C/G Intron hnRNP A1 SF2/ASF 
rs3782206 rs11068447 117747687 T/C Intron 9G8 SC35 
rs3782206 rs35736046 117747885 G/T Intron - Tra2-β 
rs3782206 rs12824048 117748042 T/C Intron 9G8 - 
rs3782206 rs36020061 117748156 C/G Intron SRp55 - 
rs3782206 rs9658309 117748304 T/A Intron - - 
rs3782206 rs9658308 117748410 G/A Intron - - 
rs3782206 rs9658297 117750695 T/C Intron hnRNP A1 9G8 
rs3782206 rs35320403 117752761 C/G Intron SRp55 SRp40 
rs499776 rs816293 117762699 G/C Intron - - 
rs499776 rs570234 117770982 G/T Intron - Tra2-β 
rs499776 rs576881 117772835 G/A Intron - - 
rs499776 rs1681506 117775578 C/T Intron - SRp40 
rs499776 rs499776 117779499 A/G Intron - SRp55 
rs41279104 rs900622 117875158 C/T Upstream E2F - 
rs41279104 rs900623 117875160 T/G Upstream - - 
rs41279104 rs41279104 117877485 T/C Upstream - - 
rs41279104 rs12316771 117879236 C/T Upstream - HOXC9,MSX1,ELF5,DLX1 
rs41279104 rs34731287 117880958 A/C Upstream - SPZ1,MAZR 
rs41279104 rs12312120 117881133 T/C Upstream HMX3 - 
rs41279104 rs17618096 117882250 C/G Upstream - - 
 
 
